Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant TumorsBusiness Wire • 10/29/20
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura BioBusiness Wire • 09/30/20
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development SummitBusiness Wire • 09/16/20
Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?Zacks Investment Research • 09/15/20
Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME StudyBusiness Wire • 09/14/20
Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company ProgressBusiness Wire • 08/10/20
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid TumorsBusiness Wire • 08/10/20
Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/30/20
Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal MelanomaBusiness Wire • 06/22/20
Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?Zacks Investment Research • 05/18/20
Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?Zacks Investment Research • 03/30/20